MedPlus Health Services Limited's Board of Directors has approved the incorporation of a wholly owned subsidiary dedicated to Corporate Social Responsibility activities. The decision was taken during the board meeting held on March 16, 2026, marking a strategic step towards structured CSR implementation.

Board Meeting Details

The board meeting commenced at 11:00 A.M and concluded at 4:50 P.M on March 16, 2026. The primary agenda involved approving the incorporation of a Private Limited Company as a Wholly Owned Subsidiary under Section 8 of the Companies Act, 2013.

Subsidiary Structure and Purpose

The new subsidiary will be established exclusively for undertaking CSR activities, operating as a not-for-profit company. Key details of the subsidiary structure include:

Financial and Regulatory Framework

The subsidiary will be capitalized through subscription to share capital at face value. The company name will be finalized upon approval by the Registrar of Companies Hyderabad. Necessary approvals will be obtained from the Registrar of Companies and other relevant authorities as required.

Compliance and Disclosure

MedPlus Health Services Limited will furnish requisite disclosures to stock exchanges upon incorporation of the wholly owned subsidiary, as mandated under SEBI Listing Regulations. The company has committed to maintaining transparency in accordance with SEBI Master Circular for listed entities dated January 30, 2026.

Corporate Governance

The decision reflects the company's commitment to structured corporate social responsibility initiatives through a dedicated subsidiary framework. This approach allows for focused management of CSR activities while maintaining compliance with regulatory requirements under Section 8 of the Companies Act, 2013.

Source: None/Company/INE804L01022/3b736750-1189-4ad4-84cb-e1181b11eea4.pdf

MedPlus Health Services has announced that its subsidiary, Optival Health Solutions Private Limited, has received multiple drug license suspensions from state authorities. The regulatory actions affect stores in Maharashtra and Odisha, representing compliance issues under the Drugs and Cosmetics Act.

Latest Regulatory Action in Odisha

The company received a new suspension order on March 09, 2026, from the Deputy Drugs Controller, Western Zone, Sambalpur, Odisha. This latest action affects a store located opposite the Private Bus Stand in Baragarh, Odisha, with a three-day suspension period.

Previous Maharashtra Suspension

Earlier, the subsidiary had received a seven-day drug license suspension from Maharashtra authorities for a store in Sangvi, Pune. This suspension order was received on March 03, 2026, from the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra.

Financial Impact Assessment

The company has quantified the potential revenue losses from both suspensions. The combined financial impact represents the expected business disruption during the suspension periods across both affected locations.

Regulatory Compliance Framework

Both suspensions fall under Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945, which govern pharmaceutical retail operations across India. Such actions by state drug control authorities typically occur when retail pharmacy operations fail to meet specific regulatory requirements or standards.

The company has disclosed this information under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding regulatory matters affecting its subsidiary operations. The disclosures follow SEBI circulars dated July 13, 2023, and December 31, 2024, regarding regulatory action reporting requirements.